McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC | McKesson
Summary
IRVING, Texas, February 4, 2025—McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services, from Quad-C. McKesson will purchase an 80% interest for approximately $850 million. We intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners and patients. McKesson has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. This will allow us to expand our suite of solutions and continue to pursue our purpose of advancing health outcomes for all.” This transaction will enable McKesson to deliver on several key strategic objectives: · Develop a leading retinal and ophthalmology platform, expanding McKesson’s differentiated value proposition, clinical services and distribution offerings. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission.